Archives of Virology

, Volume 163, Issue 6, pp 1607–1614 | Cite as

Anti-influenza virus activity of a salcomine derivative mediated by inhibition of viral RNA synthesis

  • Naoki Takizawa
  • Tomoyuki Kimura
  • Takumi Watanabe
  • Masakatsu Shibasaki
Original Article


Influenza virus infection is a major threat to global health. Although vaccines and anti-influenza virus drugs are available, annual influenza virus epidemics result in severe illness, and an influenza pandemic occurs every 20–30 years. To identify candidate anti-influenza virus compounds, we screened approximately 5,000 compounds in an in-house library. We identified MZ7465, a salcomine derivative, as a potent inhibitor of influenza virus propagation. We analyzed the antiviral propagation mechanism of the hit compound by determining the amounts of viral proteins and RNA in infected cells treated with or without the hit compound. Treatment of infected cells with MZ7465 decreased both viral protein and RNA synthesis. In addition, an in vitro assay showed that viral RNA synthesis was directly inhibited by MZ7465. These results suggest that salcomine and its derivatives are potential candidates for the treatment of influenza virus infections.



We thank Y. Iwata for providing technical support of the experiments and Dr. K. Kobayashi and Dr. Y. Kawaoka for providing MDCK and HEK293T cells, respectively.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    World Health Organization (2016) Media centre influenza (Seasonal) fact sheet. Accessed 27 Feb 2018
  2. 2.
    Lowen AC (2017) Constraints, drivers, and implications of influenza a virus reassortment. Annu Rev Virol 4:105–121. CrossRefPubMedGoogle Scholar
  3. 3.
    Takizawa N, Yamasaki M (2018) Current landscape and future prospects of antiviral drugs derived from microbial products. J Antibiot (Tokyo) 71:45–52. CrossRefGoogle Scholar
  4. 4.
    Davies WL, Grunert RR, Haff RF et al (1964) Antiviral activity of 1-adamantanamine (Amantadine). Science 144:862–863. CrossRefPubMedGoogle Scholar
  5. 5.
    Liang R, Li H, Swanson JMJ, Voth GA (2014) Multiscale simulation reveals a multifaceted mechanism of proton permeation through the influenza A M2 proton channel. Proc Natl Acad Sci 111:9396–9401. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hong M, Degrado WF (2008) Structural basis for proton conduction and inhibition by the influenza M2 protein. Nature 451:596–599. CrossRefPubMedCentralGoogle Scholar
  7. 7.
    von Itzstein M, Wu W-Y, Kok GB et al (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418–423. CrossRefGoogle Scholar
  8. 8.
    Eisenberg EJ, Bidgood A, Cundy KC (1997) Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother 41:1949–1952PubMedPubMedCentralGoogle Scholar
  9. 9.
    Smee DF, Huffman JH, Morrison AC et al (2001) Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 45:743–748. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yamashita M, Tomozawa T, Kakuta M et al (2009) CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 53:186–192. CrossRefPubMedGoogle Scholar
  11. 11.
    Furuta Y, Takahashi K, Fukuda Y et al (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977–981. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Furuta Y, Takahashi K, Kuno-Maekawa M et al (2005) Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981–986. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Neumann G, Watanabe T, Ito H et al (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci 96:9345–9350. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ishikawa Y, Eguchi H, Sato H (2013) Metal salen complex derivative and process for production thereof. Patent No. WO2011125331Google Scholar
  15. 15.
    Gallagher KJ, Webster RL (2014) Room temperature hydrophosphination using a simple iron salen pre-catalyst. Chem Commun 50:12109–12111. CrossRefGoogle Scholar
  16. 16.
    Johnson CA, Sharma S, Subramaniam B, Borovik AS (2005) Nanoparticulate metal complexes prepared with compressed carbon dioxide: correlation of particle morphology with precursor structure. J Am Chem Soc 127:9698–9699. CrossRefPubMedGoogle Scholar
  17. 17.
    Schulz J, Dettlaff S, Fritzsche U et al (1994) The amido black assay: a simple and quantitative multipurpose test of adhesion, proliferation, and cytotoxicity in microplate cultures of keratinocytes (HaCaT) and other cell types growing adherently or in suspension. J Immunol Methods 167:1–13. CrossRefPubMedGoogle Scholar
  18. 18.
    Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671–675. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kawaguchi A, Momose F, Nagata K (2011) Replication-coupled and host factor-mediated encapsidation of the influenza virus genome by viral nucleoprotein. J Virol 85:6197–6204. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Takizawa N, Watanabe K, Nouno K et al (2006) Association of functional influenza viral proteins and RNAs with nuclear chromatin and sub-chromatin structure. Microbes Infect 8:823–833. CrossRefPubMedGoogle Scholar
  21. 21.
    Takizawa N, Momose F, Morikawa Y, Nomoto A (2016) Influenza A virus hemagglutinin is required for the assembly of viral components including bundled vRNPs at the lipid raft. Viruses 8:249. CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Shimizu K, Handa H, Nakada S, Nagata K (1994) Regulation of influenza virus RNA polymerase activity by cellular and viral factors. Nucleic Acids Res 22:5047–5053. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Yamanaka K, Ishihama A, Nagata K (1990) Reconstitution of influenza virus RNA-nucleoprotein complexes structurally resembling native viral ribonucleoprotein cores. J Biol Chem 265:11151–11155PubMedGoogle Scholar
  24. 24.
    Gust R, Ott I, Posselt D, Sommer K (2004) Development of cobalt (3,4-diarylsalen) complexes as tumor therapeutics. J Med Chem 47:5837–5846. CrossRefPubMedGoogle Scholar
  25. 25.
    Watanabe S, Konno K, Shigeta S, Yokota T (1998) Inhibition of human cytomegalovirus proteinase by salcomine derivatives. Antivir Chem Chemother 9:269–274. CrossRefPubMedGoogle Scholar
  26. 26.
    Kash JC, Xiao Y, Davis AS et al (2014) Treatment with the reactive oxygen species scavenger EUK-207 reduces lung damage and increases survival during 1918 influenza virus infection in mice. Free Radic Biol Med 67:235–247. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Laboratory of VirologyInstitute of Microbial Chemistry (BIKAKEN)TokyoJapan
  2. 2.Laboratory of Synthetic Organic ChemistryInstitute of Microbial Chemistry (BIKAKEN)TokyoJapan

Personalised recommendations